A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
The decision to commence disease modifying treatments (DMTs) for MS patients was once straightforward. Since the advent of monoclonal antibodies and the first oral DMT(soon to be several) our armamentarium is increasingly complex. Guiding patients through the choices;ensuring guideline adherence;personalising risk assessment and ensuring NHS budgets are spent justifiably are paramount. We have piloted an 'MS DMT MDT'.For 12 months treatment planning has been done by the full MS Team. In 13 MDTsdoi:10.1136/jnnp-2014-309236.142 fatcat:b7hcnqdxyrf5zjnmsymtwijzea